TY
Therapeutic Areas
Agenus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Botensilimab + Balstilimab | MSS Colorectal Cancer (Chemo-refractory, Unresectable) | Phase 3 |
| MK-4830 (anti-ILT4) | Advanced Solid Tumors (combo) | Phase 1/2 |
| INCAGN2390 (anti-TIM-3) | Melanoma, SCCHN (triple combo) | Phase 1/2 |
| INCAGN2385 (anti-LAG-3) | Melanoma, SCCHN (triple combo) | Phase 1/2 |
| CR6086 + Balstilimab | pMMR-MSS Colorectal Cancer | Phase 1/2 |
| AGEN1571 (anti-ILT2) | Not specified | Not specified |
| AGEN1777 | Not specified | Not specified |
| AGEN1721 | Not specified | Not specified |